
CEO of Norwegian biotech company Bergenbio Martin Olin, who for a short time was a managing partner in venture capital firm Nordic Eye, will now be joined by a former colleague from his days at Symphogen, where Olin was in charge until October 2020 – few months after the company was sold for an estimated DKK 3bn (USD 455.7m) to French Servier.
Anders Tullgren, who was on the board of Symphogen in 2018-2019, will be the new chair of Bergenbio, the company reports in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app